Compounds > pirfenidone

Page last updated: 2024-08-23

pirfenidone and Disease, Pulmonary

pirfenidone has been researched along with Disease, Pulmonary in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (33.33)	29.6817
2010's	1 (16.67)	24.3611
2020's	3 (50.00)	2.80

Authors

Authors	Studies
Karampitsakos, T; Katsaras, M; Sotiropoulou, V; Tzouvelekis, A	1
Bardin, PG; Ruwanpura, SM; Thomas, BJ	1
Bemiss, BC; Chung, PA; Reid, M; Warrior, K	1
Dupont, LJ; Gheysens, O; Godinas, L; Goffin, KE; Heigl, T; McDonough, JE; Neyrinck, AP; Sacreas, A; Schaevers, V; Van Herck, A; Van Raemdonck, DE; Vanaudenaerde, BM; Verbeken, EK; Verleden, GM; Verleden, SE; Vos, R; Wuyts, WA; Yserbyt, J	1
Mei, S; Yao, W; Zhao, J; Zhu, Y	1
Boichot, E; Corbel, M; Germain, N; Lagente, V; Lanchou, J; Malledant, Y	1

Reviews

1 review(s) available for pirfenidone and Disease, Pulmonary

Article	Year
Pirfenidone: Molecular Mechanisms and Potential Clinical Applications in Lung Disease. American journal of respiratory cell and molecular biology, 2020, Volume: 62, Issue:4 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Proliferation; Fibroblasts; Humans; Lung; Lung Diseases; Oxidative Stress; Pyridones	2020

Other Studies

5 other study(ies) available for pirfenidone and Disease, Pulmonary

Article	Year
Improvement of psoriatic skin lesions following pirfenidone use in patients with fibrotic lung disease. BMJ case reports, 2023, Sep-27, Volume: 16, Issue:9 Topics: Humans; Lung Diseases; Psoriasis; Skin; Skin Diseases	2023
Use of Nintedanib and Pirfenidone in Non-Idiopathic Pulmonary Fibrosis Lung Disease. American journal of respiratory and critical care medicine, 2021, 07-01, Volume: 204, Issue:1 Topics: Humans; Indoles; Lung Diseases; Pyridones	2021
Pirfenidone in restrictive allograft syndrome after lung transplantation: A case series. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2018, Volume: 18, Issue:12 Topics: Allografts; Anti-Inflammatory Agents, Non-Steroidal; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Humans; Lung Diseases; Lung Transplantation; Male; Middle Aged; Postoperative Complications; Primary Graft Dysfunction; Prognosis; Pulmonary Fibrosis; Pyridones; Retrospective Studies; Risk Factors; Syndrome	2018
Protection of pirfenidone against an early phase of oleic acid-induced acute lung injury in rats. The Journal of pharmacology and experimental therapeutics, 2005, Volume: 313, Issue:1 Topics: Animals; Anti-Inflammatory Agents; Blood Gas Analysis; Electron Spin Resonance Spectroscopy; Lung; Lung Diseases; Male; Oleic Acid; Organ Size; Pyridones; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species	2005
Modulation of airway remodeling-associated mediators by the antifibrotic compound, pirfenidone, and the matrix metalloproteinase inhibitor, batimastat, during acute lung injury in mice. European journal of pharmacology, 2001, Aug-24, Volume: 426, Issue:1-2 Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bronchoalveolar Lavage Fluid; Cell Count; Inflammation Mediators; Lipopolysaccharides; Lung; Lung Diseases; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Mice; Mice, Inbred BALB C; Phenylalanine; Pyridones; Thiophenes; Tissue Inhibitor of Metalloproteinases; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha	2001